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Background: Non-functional endocrine pancreatic tumours (NPT) of more than 2 cm have an increased
risk of malignancy. The aim of the present study was: (i) to define the guidelines for laparoscopic
enucleation (LapEn) in patients with a non-functional NPT 3 cm in diameter; (ii) to evaluate pancreas-
related complications; and (iii) to present the long-term outcome.
Methods: Between April 1998 and September 2010, 30 consecutive patients underwent laparoscopic
surgery for a non-functional NPT (median age 56.5 years, range 44–83). Only 13 patients with tumours
3 cm in size underwent LapEn. Local lymph node dissection to exclude lymph node involvement was
performed in all patients.
Results: The median tumour size, operative time and blood loss were 2.8 cm (range 2.8–3), 130 min
(range 90–280) and 220 ml (range 120–300), respectively. A pancreatic fistula occurred in five patients:
International Study Group of Pancreatic Fistula (ISGPF) A in two patients and ISGPF B in three patients.
The median follow-up was 48 months (12–144). Three patients with well-differentiated carcinoma are free
of disease 2, 3 and 4 years after LapEn and a regional lymphadenectomy. One patient, 5 years after a
LapEn, presented with lymph node and liver metastases.
Conclusions: The present study confirms the technical feasibility and acceptable morbidity associated
with LapEn. Intra-operative lymph node sampling and frozen-section examination should be performed at
the time of LapEn; when a malignancy is confirmed, oncologically appropriate lymph node dissection
should be performed.
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Introduction
Neuroendocrine pancreatic tumours (NPT) are a rare group of
neoplasms with complex patterns of behaviour requiring detailed
specialist management. Surgery remains the only curative modal-
ity currently available for resectable NPT. Complete surgical resec-
tion may be possible in those tumours that are localized at
presentation. The surgical management varies according to
tumour type, location and size. Functional and non-functional
NPT 3 cm in diameter may be treated with enucleation.1–3
In 1996, Gagner et al.1 reported an early experience with lap-
aroscopic resection (LPR) of islet cell tumours. Since then, the
majority of reports on LPR are based on limited experience with
a short follow-up.2–14 In a recent systematic review of laparoscopic
enucleation of pancreatic tumours by Briggs et al.,4 the conversion
rate ranged from 10.5% to 44.4%, and the morbidity associated
with the procedure ranged from 22% to 66.6%.
Presently, pancreatic enucleation is considered the procedure of
choice to treat insulinomas.5–15 Non-functional tumours are a
poorly understood group of lesions that may behave more aggres-
sively.16 Only non-functional NPT with a low likelihood of malig-
nancy (<3 cm in size, no enlarged locoregional lymph nodes or no
distant metastasis) can be treated with enucleation. In the context
of NPT, the semantics of benign vs. malignant have to be viewed
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with caution. A small non-functional NPT that has been com-
pletely enucleated may be found years later to have lymph nodes
and liver metastases.16,17 Based on this behaviour, in patients with
non-functional NPT, nodal sampling should be routinely per-
formed during enucleation to rule out metastatic disease and to
increase the diagnostic effectiveness.
We have previously reported5 the outcome of 16 patients with
non-functional pancreatic tumours. In the present study, a further
14 patients have been added.
The aim of the present study was: (i) to define the guidelines for
laparoscopic enucleation (LapEn) in patients with non-functional
NPT; (ii) to evaluate pancreas-related complications after a
LapEn; and (iii) to present the long-term outcome.
Methods
Laparoscopic pancreatic resections were carried out at the Hospi-
tal Clínic de Barcelona.
The diagnosis and location of a non-functional NPT was estab-
lished with a combination of endoscopic ultrasonography and
computed tomography. Magnetic resonance imaging was per-
formed to define the anatomic relation between the tumour and
the main pancreatic duct.
The technical details of LapEn have been previously published.18
The use of intra-operative laparoscopic ultrasonography (LapUS)
was an integral part of the procedure. All patients were managed
with local lymph node dissection to exclude metastatic lymph
node involvement. Local lymphadenectomy varied depending on
the localization of the tumour. For tumours located in the pancre-
atic head, lymph node sampling was performed from lymph node
stations 8 (lymph nodes around the common hepatic artery), 14
(lymph nodes around the superior mesenteric artery) and 17
(anterior pancreaticoduodenal lymph nodes) as defined by the
Japanese Pancreas Society.19 For tumours located in the body-tail
of the pancreas, lymph node sampling was performed from lymph
node stations 8, 9 (lymph nodes around the celiac trunk), 11
(lymph nodes around the splenic artery) and 18 (lymph nodes
along the inferior border of the body and tail of the pancreas),
as defined by the Japanese Pancreas Society19 (Figs 1,2). When
frozen section examination revealed malignancy, a complete lym-
phadenectomy of the involved lymph node station was performed.
Data were collected prospectively. Patient demographics and
intra-operative parameters, including total operative time, blood
loss and blood transfusions, were recorded. Post-operative events
were recorded using the following definitions.
• Pancreatic fistula (PF), according to the International Study
Group on Pancreatic Fistula (ISGPF).20
• Splenic complications: splenic infarct, focal or massive, detected
by colour Doppler ultrasonography (CD-US).
• Abscess: culture-positive purulent drainage from an intra-
abdominal fluid collection obtained percutaneously or intra-
operatively, and/or radiographically-confirmed fluid collection,
with systemic or localized signs of infection.
• Pneumonia: presence of a new infiltrate on chest radiograph,
with the following: temperature >38°C; abnormal elevation of
white blood count; or positive symptoms Gram stain or culture,
and requiring intravenous antibiotic treatment.
• Length of hospital stay (LHS): days from the initial operation to
hospital discharge.
• Conversion: need for an abdominal incision to deal with any
intra-operative complication; the need to make an abdominal
incision when a safe dissection is not possible on oncological
grounds.
All tumours were classified according to the World Health
Organization (WHO) classification,21 Table 1.
Results
A total of 30 consecutive patients with a non-functional NPT
between April 1998 and September 2010 underwent laparoscopic
pancreatic surgery (median age 56.5 years, range 44 to 83).
Only 13 patients with tumours 3 cm in size (median 2.8 cm
and range 2.8–3 cm) underwent LapEn. Lymph node sampling of
the areas in close proximity to the LapEn was performed in all
patients, and these samples were sent for frozen-section exami-
nation. In three patients with tumours localized in the head
(n = 1) and the body (n = 2) of the pancreas, the pathological
report was positive for lymph node metastases. Lymph node dis-
section was performed in one patient along the hepatic artery
(area 8), superior mesenteric vein (area 14) and anterior head of
the pancreas (area 17); ten lymph nodes were retrieved, and 2
from station 8 were malignant. In two other patients, a regional
lymphadenectomy was performed, including area 8 (hepatic
artery), 9 (celiac trunk), 11 (splenic artery) and 18 (inferior
border of the pancreas); eight and 9 lymph nodes, respectively,
were retrieved and malignancy was found in one (1/5) node from
station 11 in one patient, and in 2 (2/4) nodes from station 18 in
the other patient.
The median operating time was 130 min (range 90–280) and
the median blood loss was 220 ml (120–300).
A pancreatic fistula occurred in five patients: International
Study Group on Pancreatic Fistula (ISGPF) A in two patients and
ISGPF B in three patients.
According to the WHO classification,22 10 patients were classi-
fied as uncertain behaviour and 3 patients had tumours with
evidence of malignancy (well differentiated carcinoma).
There were no deaths in the series. The median LHS was 6 days
(range 6–7).
The median follow-up and range was 48 (12–144) months,
respectively. All three patients with lymph node metastases at the
time of LapEn and regional lymphadenectomy are free of disease
2, 3 and 4 years after surgery. In the course of the study, one
patient 5 years after LapEn for non-functional uncertain behav-
iour tumour presented with lymph node and liver metastases
(segments II and III) which were successfully resected using a
laparoscopic approach.
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Discussion
The operative approach to NPT is still a matter of debate. Enucle-
ation has become an alternative procedure in patients with
benign-appearing tumours. The potential advantages of this less
invasive procedure are less blood loss and better preservation
of pancreatic function. Therefore, enucleation has become an
accepted procedure for the treatment of insulinoma.5–14 The
Figure 1 Complete laparoscopic enucleation of a tumour located in the pancreatic head. Caution should be taken to avoid injury of the
Wirsung duct. Lymph node sampling of the areas around the hepatic artery (8), anterior pancreatoduodenal (17) and superior mesenteric vein
(14); numbers correspond to areas according to the Japanese Pancreas Society
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Figure 2 Laparoscopic enucleation of tumours located in the body of the pancreas. Depending on the location of the tumour, lymph node
sampling along the splenic artery (11) and at the inferior border of the pancreas (18); numbers correspond to areas according to the Japanese
Pancreas Society
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question of laparoscopic enucleation in non-functional NPT is
still not settled.
Enucleation for NPT is not a simple procedure, whether per-
formed open or laparoscopically. In addition, pancreas-related
complications may occur. In an international review of benign
insulinomas treated by open surgery, Rothmund et al.22 reported a
complication rate of 32%. Hellman et al.23 evaluated the outcome
of 65 patients operated on for organic hiperinsulinism using the
open approach. A pancreatic fistula occurred after enucleation
from the head in 50%, from the body-tail of the pancreas in 24%
and after distal pancreatectomy in 26%. Park et al.24 reported that
experience with open surgical treatment in patients with islet cell
tumours arising in the head of the pancreas (70% sporadic insuli-
noma). In 22 patients with simple enucleation, the mean operative
time was 4 h, the mean blood loss 360 ml, the median time for
return to regular diet 7 days and the median time to drain removal
22 days. In that previous series, 67% of patients had no compli-
cations; however, a PF, requiring intravenous alimentation and
prolonged hospital stay, occurred in 15% of patients. We interpret
this as a grade C pancreatic fistula according to ISGPF. Further-
more, 12 patients (44%) had some amount of amylase-rich fluid
drainage (biochemical grade A fistula). Other complications
observed were pancreatitis (4%), an intra-abdominal abscess
(4%), post-operative bleeding (4%) and delayed gastric emptying
(4%). Crippa et al.25 reported 61 consecutive patients who under-
went pancreatic enucleation, among whom 38 had neuroendo-
crine tumours (22 insulinomas and 16 non-functional tumors).
Open enucleation was performed in 93% of patients and LapEn in
7%. Overall morbidity was 43%. Pancreatic fistula was also
reported in 38% of patients (ISGPF type A 39%, type B 43%, and
type C 18%). Reoperation was performed in 8% of patients. The
mean LHS was 9 days.
Recently, Pitt et al.26 in a multi-institutional retrospective
review compared the outcomes of enucleation and resection in 87
patients with a small NPT. The pancreatic fistula rate was 38%
after enucleation (ISGPF type A 57%, type B 43%) and 15% after
resection (ISGPF type A 23%, type B 62%, and type C 15%).
Length of hospital stay after enucleation and resection were 9 and
10 days, respectively. The authors concluded that, although
enucleated patients had a higher incidence of a PF formation
compared with the resection group, the fistulas that formed after
resection were more clinically significant (grades B and C).
Recently, Dedieu et al.27 summarized the series of LapEn for
cystic tumours and NPT. Mortality was 4%, morbidity 7%–60%,
pancreatic fistula rate 13%–50%, re-operation rate 0%–8% and
LHS 9–19.5 days.
Compared with small, benign insulinomas that are readily
curable by surgical resection,5–14 non-functional NPT have a much
less-favourable prognosis.16,17 Approximately 50% to 80% of these
neoplasms will have a recurrence or metastasize, and up to one-
third of the patients already have metastases at initial presenta-
tion. The present study has demonstrated the feasibility and safety
of LapEn for a non-functional NPT 3 cm. However, one of the
concerns in the management of non-functional NPT is the ques-
tion of malignancy. At the time of LapEn the distinction between
benign and malignant is difficult. Although macroscopically most
tumours appear well demarcated, they often fail to exhibit a well-
defined capsule and are usually white-grey to pinkish-brown and
of firm consistency. The clearest evidence of malignancy is pro-
vided by local or capsular invasion or the presence of lymph node
metastases. In the present study, three patients were found with
lymph node metastases at the time of LapEn. Recently, Edil et al.28
reported the outcome of the surgical treatment of 218 sporadic,
non-functional NPT. In all, 140 patients (44%) had positive
lymph nodes. Tumour size was associated with lymph node
metastasis: <1 cm: 14%; 1–1.9 cm: 9%; 2–2.9 cm: 37%; 3–3.9 cm:
56%; 4–4.9 cm: 72%; and 5 cm: 56%. The previous authors
concluded that size of NPT correlates with lymph node
metastases, and even small, <1 cm NPT metastasize to lymph
nodes. Lymph node metastases, furthermore, correlate with sur-
vival. We believe lymph node sampling should be mandatory to
rule out malignancy. Lymph node dissection should be performed
after LapEn as an oncologically sound operation. So far, there is no
evidence that a more extended pancreatic resection will result in
less recurrence and better patient survival.
Conclusion
Surgical resection is the treatment of choice for patients with NPT.
For small tumours 3 cm, NPT enucleation preserves healthy
parenchyma and pancreatic function. In addition, the laparo-
scopic approach offers clear advantages to the patients in terms of
reduced parietal damage in the abdomen. It seems that the risk of
PF is high after LapEn for tumours in the pancreatic head vs. those
Table 1 Clinicopathological features of pancreatic neuroendocrine neoplasms
Classification Classes Criteria
WHO 1 Well-differentiated tumour
1.1 Benign <2 cm contained in the pancreas, no angioinvasion/perineural invasion, 2 mitoses/
10 HPF, <2% Ki-67
1.2 Uncertain 2 cm contained in the pancreas, angioinvasion/perineural invasion, >2–10 mitoses/
10 HPF, >2% Ki-67
2 Well-differentiated carcinoma Low-grade malignant, gross local invasion and/or metastases
3 Poorly-differentiated carcinoma High-grade malignant >10/10 HPF, >16% Ki-67
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located in the body-tail. The present study provides evidence for
the surgical strategy in patients with non-functional NPT. Intra-
operative lymph node sampling and frozen-section examination
should be part of the evaluation in patients with non-functional
NPT. When malignancy is confirmed the surgeon may continue
with LapEn provided an oncologically appropriate lymph node
dissection is performed.
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